What question did this study set out to answer?

The project aims to develop an effective method for purifying and enhancing the delivery of Moenomycin A to combat antibiotic resistance.

March 4, 2026Journal of Higher Education Research0 citationsOpen Access

Novel Purification and Testing of the Antimicrobial Agent Moenomycin A Using Starbon® A300 and Enhancement of in vivo Efficacy with n-dodecyl-β-D-maltoside.

LELeon Erith RMRob McElroy ETEdward Taylor

Key Points

The project aims to develop an effective method for purifying and enhancing the delivery of Moenomycin A to combat antibiotic resistance.
Cultured Streptomyces viridosporus DSM 40746 on TSB media.
Purified the extract using Starbon® A300.
Measured the antimicrobial activity against Bacillus subtilis by quantifying inhibition effects.
Investigated n-dodecyl-β-D-maltoside (DDM) to reduce Moenomycin A's binding to blood plasma proteins.
Achieved successful purification of Moenomycin A using Starbon® A300.
Demonstrated enhanced antimicrobial activity with DDM involvement.
Reduced minimum inhibitory concentration (MIC) of Moenomycin A, improving its potential for clinical use.

Abstract

Antibiotic resistance is a growing global health crisis. This project aims to develop a new purification and delivery method for Moenomycin A, a novel antibiotic. The single-step purification method includes culturing Streptomyces viridosporus DSM 40746 on TSB media, purifying the extract and spent culture media utilising Starbon® A300 and measuring the purified extracts antimicrobial activity by quantifying its inhibitory effects on the growth of a Bacillus subtilis lawn. This project also addresses Moenomycin A’s unfavourable binding with blood plasma proteins, a major limitation of Moenomycin A for clinical use. n-dodecyl-β-D-maltoside (DDM) and PEG400 were investigated to mitigate this binding in order to decrease Moenomycin A’s minimum inhibitory concentration (MIC).

AIに質問

Bookmark

View Full Paper